|
1
|
Recabarren D and Alarcon M: Gene networks
in neurodegenerative disorders. Life Sci. 183:83–97.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pihlstrøm L, Wiethoff S and Houlden H:
Genetics of neurodegenerative diseases: An overview. Handb Clin
Neurol. 145:309–323. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shen T, You Y, Joseph C, Mirzaei M,
Klistorner A, Graham SL and Gupta V: BDNF polymorphism: A review of
its diagnostic and clinical relevance in neurodegenerative
disorders. Aging Dis. 9(523)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Guzman-Martinez L, Maccioni RB, Andrade V,
Navarrete LP, Pastor MG and Ramos-Escobar N: Neuroinflammation as a
common feature of neurodegenerative disorders. Front Pharmacol.
10(1008)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ma MW, Wang J, Zhang Q, Wang R, Dhandapani
KM, Vadlamudi RK and Brann DW: NADPH oxidase in brain injury and
neurodegenerative disorders. Mol Neurodegener. 12(7)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mendez MF: Early-onset Alzheimer disease
and its variants. Continuum (Minneap Minn). 25:34–51.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bakels HS, Roos RAC, van Roon-Mom WMC and
de Bot ST: Juvenile-Onset huntington disease pathophysiology and
neurodevelopment: A review. Mov Disord. 37:16–24. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kumar A, Kumar V, Singh K, Kumar S, Kim
YS, Lee YM and Kim JJ: Therapeutic advances for Huntington's
disease. Brain Sci. 10(43)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yanagisawa N: The spectrum of motor
disorders in Huntington's disease. Clin Neurol Neurosurg. 94
(Suppl):S182–S184. 1992.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bonner-Jackson A, Long JD, Westervelt H,
Tremont G, Aylward E and Paulsen JS: PREDICT-HD Investigators and
Coordinators of the Huntington Study Group. Cognitive reserve and
brain reserve in prodromal Huntington's disease. J Int Neuropsychol
Soc. 19:739–750. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Harrington DL, Liu D, Smith MM, Mills JA,
Long JD, Aylward EH and Paulsen JS: Neuroanatomical correlates of
cognitive functioning in prodromal Huntington disease. Brain Behav.
4:29–40. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Epping EA, Mills JA, Beglinger LJ,
Fiedorowicz JG, Craufurd D, Smith MM, Groves M, Bijanki KR, Downing
N, Williams JK, et al: Characterization of depression in prodromal
Huntington disease in the neurobiological predictors of HD
(PREDICT-HD) study. J Psychiatr Res. 47:1423–1431. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
van Dijk JG, van der Velde EA, Roos RA and
Bruyn GW: Juvenile huntington disease. Hum Genet. 73:235–239.
1986.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Siesling S, Vegter-van der Vlis M and Roos
RA: Juvenile Huntington disease in the Netherlands. Pediatr Neurol.
17:37–43. 1997.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wexler NS, Lorimer J, Porter J, Gomez F,
Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA,
Gayán J, et al: Venezuelan kindreds reveal that genetic and
environmental factors modulate Huntington's disease age of onset.
Proc Natl Acad Sci USA. 101:3498–3503. 2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Quarrell OWJ, Brewer HM, Squitieri F,
Barker R, Nance MA and Lanswehrmeyer BG: ‘Juvenile Huntington's
Disease (and other trinucleotide repeat disorders)’. Oxford
University Press, Oxford, 2009.
|
|
17
|
Gatto EM, Parisi V, Etcheverry JL,
Sanguinetti A, Cordi L, Binelli A, Persi G and Squitieri F:
Juvenile Huntington disease in Argentina. Arq Neuropsiquiatr.
74:50–54. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tereshchenko A, Magnotta V, Epping E,
Mathews K, Espe-Pfeifer P, Martin E, Dawson J, Duan W and Nopoulos
P: Brain structure in juvenile-onset Huntington disease. Neurology.
92:e1939–e1947. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
van der Plas E, Langbehn DR, Conrad AL,
Koscik TR, Tereshchenko A, Epping EA, Magnotta VA and Nopoulos PC:
Abnormal brain development in child and adolescent carriers of
mutant huntingtin. Neurology. 93:e1021–e1030. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gusella JF, Wexler NS, Conneally PM,
Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR,
Sakaguchi AY, et al: A polymorphic DNA marker genetically linked to
Huntington's disease. Nature. 306:234–238. 1983.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
A novel gene containing a trinucleotide
repeat that is expanded and unstable on Huntington's disease
chromosomes. The Huntington's Disease Collaborative Research Group.
Cell. 72:971–983. 1993.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Saudou F and Humbert S: The biology of
Huntingtin. Neuron. 89:910–926. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schultz JL, van der Plas E, Langbehn DR,
Conrad AL and Nopoulos PC: Age-Related cognitive changes as a
function of CAG repeat in child and adolescent carriers of mutant
Huntingtin. Ann Neurol. 89:1036–1040. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Andrew SE, Goldberg YP, Kremer B, Telenius
H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA,
et al: The relationship between trinucleotide (CAG) repeat length
and clinical features of Huntington's disease. Nat Genet.
4:398–403. 1993.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Squitieri F and Jankovic J: Huntington's
disease: How intermediate are intermediate repeat lengths? Mov
Disord. 27:1714–1717. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ho LW, Brown R, Maxwell M, Wyttenbach A
and Rubinsztein DC: Wild type Huntingtin reduces the cellular
toxicity of mutant Huntingtin in mammalian cell models of
Huntington's disease. J Med Genet. 38:450–452. 2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Shirasaki DI, Greiner ER, Al-Ramahi I,
Gray M, Boontheung P, Geschwind DH, Botas J, Coppola G, Horvath S,
Loo JA and Yang XW: Network organization of the huntingtin
proteomic interactome in mammalian brain. Neuron. 75:41–57.
2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nuzzo MT and Marino M:
Estrogen/Huntingtin: A novel pathway involved in neuroprotection.
Neural Regen Res. 11:402–403. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Leavitt BR, van Raamsdonk JM, Shehadeh J,
Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA and
Hayden MR: Wild-type huntingtin protects neurons from
excitotoxicity. J Neurochem. 96:1121–1129. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ismailoglu I, Chen Q, Popowski M, Yang L,
Gross SS and Brivanlou AH: Huntingtin protein is essential for
mitochondrial metabolism, bioenergetics and structure in murine
embryonic stem cells. Dev Biol. 391:230–240. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Guedes-Dias P, Pinho BR, Soares TR, de
Proença J, Duchen MR and Oliveira JM: Mitochondrial dynamics and
quality control in Huntington's disease. Neurobiol Dis. 90:51–57.
2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Brustovetsky N: Mutant huntingtin and
elusive defects in oxidative metabolism and mitochondrial calcium
handling. Mol Neurobiol. 53:2944–2953. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Grima JC, Daigle JG, Arbez N, Cunningham
KC, Zhang K, Ochaba J, Geater C, Morozko E, Stocksdale J, Glatzer
JC, et al: Mutant Huntingtin disrupts the nuclear pore complex.
Neuron. 94:93–107.e6. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zeitlin S, Liu JP, Chapman DL, Papaioannou
VE and Efstratiadis A: Increased apoptosis and early embryonic
lethality in mice nullizygous for the Huntington's disease gene
homologue. Nat Genet. 11:155–163. 1995.PubMed/NCBI View Article : Google Scholar
|
|
35
|
McKinstry SU, Karadeniz YB, Worthington
AK, Hayrapetyan VY, Ozlu MI, Serafin-Molina K, Risher WC, Ustunkaya
T, Dragatsis I, Zeitlin S, et al: Huntingtin is required for normal
excitatory synapse development in cortical and striatal circuits. J
Neurosci. 34:9455–9472. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Mehler MF, Petronglo JR, Arteaga-Bracho
EE, Gulinello ME, Winchester ML, Pichamoorthy N, Young SK, DeJesus
CD, Ishtiaq H, Gokhan S and Molero AE: Loss-of-Huntingtin in medial
and lateral ganglionic lineages differentially disrupts regional
interneuron and projection neuron subtypes and promotes
Huntington's disease-associated behavioral, cellular, and
pathological Hallmarks. J Neurosci. 39:1892–1909. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Jung R, Lee Y, Barker D, Correia K, Shin
B, Loupe J, Collins RL, Lucente D, Ruliera J, Gillis T, et al:
Mutations causing Lopes-Maciel-Rodan syndrome are huntingtin
hypomorphs. Hum Mol Genet. 30:135–148. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lackie RE, Maciejewski A, Ostapchenko VG,
Marques-Lopes J, Choy WY, Duennwald ML, Prado VF and Prado MAM: The
Hsp70/Hsp90 chaperone machinery in neurodegenerative diseases.
Front Neurosci. 11(254)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Qi L, Zhang XD, Wu JC, Lin F, Wang J,
DiFiglia M and Qin ZH: The role of chaperone-mediated autophagy in
huntingtin degradation. PLoS One. 7(e46834)2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Keum JW, Shin A, Gillis T, Mysore JS, Abu
Elneel K, Lucente D, Hadzi T, Holmans P, Jones L, Orth M, et al:
The HTT CAG-Expansion mutation determines age at death but not
disease duration in huntington disease. Am J Hum Genet. 98:287–298.
2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dulski J, Sulek A, Krygier M, Radziwonik W
and Slawek J: False-negative tests in Huntington's disease: A new
variant within primer hybridization site. Eur J Neurol.
28:2103–2105. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
De Luca A, Morella A, Consoli F, Fanelli
S, Thibert JR, Statt S, Latham GJ and Squitieri F: A Novel
Triplet-Primed PCR assay to detect the full range of trinucleotide
CAG repeats in the huntingtin gene (HTT). Int J Mol Sci.
22(1689)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Langfelder P, Gao F, Wang N, Howland D,
Kwak S, Vogt TF, Aaronson JS, Rosinski J, Coppola G, Horvath S and
Yang XW: MicroRNA signatures of endogenous Huntingtin CAG repeat
expansion in mice. PLoS One. 13(e0190550)2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Reed ER, Latourelle JC, Bockholt JH, Bregu
J, Smock J, Paulsen JS and Myers RH: PREDICT-HD CSF Ancillary Study
Investigators. MicroRNAs in CSF as prodromal biomarkers for
Huntington disease in the PREDICT-HD study. Neurology.
90:e264–e272. 2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Glidden AM, Luebbe EA, Elson MJ,
Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER and Heatwole CR:
Patient-reported impact of symptoms in Huntington disease:
PRISM-HD. Neurology. 94:e2045–e2053. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Paulsen JS, Miller AC, Hayes T and Shaw E:
Cognitive and behavioral changes in Huntington disease before
diagnosis. Handb Clin Neurol. 144:69–91. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Oosterloo M, de Greef BTA, Bijlsma EK,
Durr A, Tabrizi SJ, Estevez-Fraga C, de Die-Smulders CEM and Roos
RAC: Disease onset in Huntington's disease: When is the conversion?
Mov Disord Clin Pract. 8:352–360. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Squadrone S, Brizio P, Abete MC and Brusco
A: Trace elements profile in the blood of Huntington' disease
patients. J Trace Elem Med Biol. 57:18–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Caron NS, Wright GEB and Hayden MR:
Huntington Disease. 1998 Oct 23 (updated 2020 Jun 11). In:
GeneReviews® (Internet). Adam MP, Ardinger HH, Pagon RA,
Wallace SE, Bean LJH, Mirzaa G and Amemiya A (eds). University of
Washington, Seattle, WA, 1993-2021.
|
|
50
|
Shoulson I and Young AB: Milestones in
huntington disease. Mov Disord. 26:1127–1133. 2011.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Pringsheim T, Wiltshire K, Day L, Dykeman
J, Steeves T and Jette N: The incidence and prevalence of
Huntington's disease: A systematic review and meta-analysis. Mov
Disord. 27:1083–1091. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sobel SK and Cowan DB: Impact of genetic
testing for Huntington disease on the family system. Am J Med
Genet. 90:49–59. 2000.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Migliore S, Jankovic J and Squitieri F:
Genetic Counseling in Huntington's disease: Potential new
challenges on Horizon? Front Neurol. 10(453)2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
MacLeod R, Metcalfe A and Ferrer-Duch M: A
family systems approach to genetic counseling: Development of
narrative inter-ventions. J Genet Couns. 30:22–29. 2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pierron L, Hennessy J, Tezenas du Montcel
S, Coarelli G, Heinzmann A, Schaerer E, Herson A, Petit E, Gargiulo
M and Durr A: Informing about genetic risk in families with
Huntington disease: Comparison of attitudes across two decades. Eur
J Hum Genet. 29:672–679. 2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Barker RA, Fujimaki M, Rogers P and
Rubinsztein DC: Huntingtin-lowering strategies for Huntington's
disease. Expert Opin Investig Drugs. 29:1125–1132. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Aziz NA, van der Burg JMM, Tabrizi SJ and
Landwehrmeyer GB: Overlap between age-at-onset and
disease-progression determinants in Huntington disease. Neurology.
90:e2099–e2106. 2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Tabrizi SJ, Ghosh R and Leavitt BR:
Huntingtin lowering strategies for disease modification in
Huntington's disease,. Neuron. 101:801–819. 2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Lane RM, Smith A, Baumann T, Gleichmann M,
Norris D, Bennett CF and Kordasiewicz H: Translating antisense
technology into a treatment for Huntington's disease. Methods Mol
Biol. 1780:497–523. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB,
Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J,
Rickards H, et al: Targeting Huntingtin expression in patients with
Huntington's disease. N Engl J Med. 380:2307–2316. 2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Harper SQ, Staber PD, He X, Eliason SL,
Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL and Davidson BL:
RNA interference improves motor and neuropathological abnormalities
in a Huntington's disease mouse model. Proc Natl Acad Sci USA.
102:5820–5825. 2005.PubMed/NCBI View Article : Google Scholar
|
|
62
|
DiFiglia M, Sena-Esteves M, Chase K, Sapp
E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, et
al: Therapeutic silencing of mutant huntingtin with siRNA
attenuates striatal and cortical neuropathology and behavioral
deficits. Proc Natl Acad Sci USA. 104:17204–17209. 2007.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Keiser MS, Kordasiewicz HB and McBride JL:
Gene suppression strategies for dominantly inherited
neurodegenerative diseases: Lessons from Huntington's disease and
spinocerebellar ataxia. Hum Mol Genet. 25(R1):R53–R64.
2016.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Yu D, Pendergraff H, Liu J, Kordasiewicz
HB, Cleveland DW, Swayze EE, Lima WF, Crooke ST, Prakash TP and
Corey DR: Single-stranded RNAs use RNAi to potently and
allele-selectively inhibit mutant huntingtin expression. Cell.
150:895–908. 2012.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Dufour BD, Smith CA, Clark RL, Walker TR
and McBride JL: Intrajugular vein delivery of AAV9-RNAi prevents
neuropathological changes and weight loss in Huntington's disease
mice. Mol Ther. 22:797–810. 2014.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Miniarikova J, Zanella I, Huseinovic A,
van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL,
Hayden MR, van Deventer SJ, et al: Design, Characterization, and
lead selection of therapeutic miRNAs targeting huntingtin for
development of gene therapy for Huntington's disease. Mol Ther
Nucleic Acids. 5(e297)2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Devi S, Kumar V, Singh SK, Dubey AK and
Kim JJ: Flavonoids: Potential candidates for the treatment of
neurodegenerative disorders. Biomedicines. 9(99)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Huntington Study Group. Tetrabenazine as
antichorea therapy in Huntington disease: A randomized controlled
trial. Neurology. 66:366–372. 2006.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Arora A, Kumar S, Ali J and Baboota S:
Intranasal delivery of tetrabenazine nanoemulsion via olfactory
region for better treatment of hyperkinetic movement associated
with Huntington's disease: Pharmacokinetic and brain delivery
study. Chem Phys Lipids. 230(104917)2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Catanesi M, Caioni G, Castelli V,
Benedetti E, d'Angelo M and Cimini A: Benefits under the Sea: The
role of marine compounds in neurodegenerative disorders. Mar Drugs.
19(24)2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Jabłońska M, Grzelakowska K, Wiśniewski B,
Mazur E, Leis K and Gałązka P: Pridopidine in the treatment of
Huntington's disease. Rev Neurosci. 31:441–451. 2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Squitieri F, Di Pardo A, Favellato M,
Amico E, Maglione V and Frati L: Pridopidine, a dopamine
stabilizer, improves motor performance and shows neuroprotective
effects in Huntington disease R6/2 mouse model. J Cell Mol Med.
19:2540–2548. 2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Garcia-Miralles M, Geva M, Tan JY, Yusof
NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, et al:
Early pridopidine treatment improves behavioral and transcriptional
deficits in YAC128 Huntington disease mice. JCI insight.
2(e95665)2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Bartl S, Oueslati A, Southwell AL, Siddu
A, Parth M, David LS, Maxan A, Salhat N, Burkert M, Mairhofer A, et
al: Inhibiting cellular uptake of mutant huntingtin using a
monoclonal antibody: Implications for the treatment of Huntington's
disease. Neurobiol Dis. 141(104943)2020.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Connor B: Concise review: The use of stem
cells for understanding and treating Huntington's disease. Stem
Cells. 36:146–160. 2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Fritz NE, Rao AK, Kegelmeyer D, Kloos A,
Busse M, Hartel L, Carrier J and Quinn L: Physical therapy and
exercise interventions in Huntington's disease: A mixed methods
systematic review. J Huntingtons Dis. 6:217–235. 2017.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Roos RA: Huntington's disease: A clinical
review. Orphanet J Rare Dis. 5(40)2010.PubMed/NCBI View Article : Google Scholar
|
